3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
28
Carcinoma, Hepatocellular
25
Colorectal Neoplasms
23
Carcinoma, Non-Small-Cell Lung
13
Melanoma
12
Stomach Neoplasms
10
Colonic Neoplasms
10
Liver Neoplasms
9
Neoplasm Metastasis
8
Squamous Cell Carcinoma of Head and Neck
7
Carcinoma, Transitional Cell
7
Carcinoma, Renal Cell
7
Uterine Cervical Neoplasms
6
Rectal Neoplasms
6
Ovarian Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Prostatic Neoplasms
5
Lung Neoplasms
5
Gastrointestinal Stromal Tumors
5
Esophageal Neoplasms
5
Carcinoma
5
Urinary Bladder Neoplasms
4
Turcot syndrome
4
Triple Negative Breast Neoplasms
4
Small Cell Lung Carcinoma
4
Sarcoma
4
Mesothelioma
4
Endometrial Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Merkel Cell
4
Interventions
apatinib
9
Paclitaxel
9
Capecitabine
7
Oxaliplatin
6
camrelizumab
5
Cisplatin
5
S 1 (combination)
4
Fluorouracil
3
Docetaxel
3
130-nm albumin-bound paclitaxel
3
titanium silicide
2
Leucovorin
2
Drug Therapy
2
vorolanib
1
trifluridine tipiracil drug combination
1
tipiracil
1
spartalizumab
1
rucaparib
1
relatlimab
1
raltitrexed
1
pazopanib
1
olaparib
1
lobaplatin
1
linrodostat
1
ezogabine
1
endostar protein
1
durvalumab
1
dacomitinib
1
capivasertib
1
Trifluridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Gastric Cancer
×
Ipilimumab
×
Gastrointestinal
×
Clear all
NCT02935634
2023-06-09
FRACTION-GC
Bristol-Myers Squibb
Phase 2
Completed
190 enrolled
25 charts